FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087788702> ?p ?o ?g. }

• W3087788702 abstract "Background: Despite the acknowledged benefits of immune checkpoint inhibitor (ICI)-based combination therapy (either with other checkpoint inhibitors, chemotherapy, targeted therapy, or radiotherapy), little is known about the impact of age on the efficacy of ICI -based combination therapy in non-small-cell lung cancer (NSCLC) patients. We conducted a systematic review and meta-analysis to investigate the differences in the benefits of ICI-based combination therapy for NSCLC by age (cut-off age, 65 years). Methods: We systematically searched randomized controlled trials (RCTs) of ICI plus other therapies including other ICIs, chemotherapies, targeted therapies, or radiotherapies, in the PubMed, Embase, and Cochrane databases with available hazard ratios (HRs) and 95% confidence intervals (CIs) for death and disease progression according to patient age. The search deadline was May 25, 2020. First, we calculated the pooled HRs of younger and older patients based on the HRs from each trial. Second, we assessed the pooled ratio of HRs reported in older patients to the HRs reported in younger patients for progression or death by the random-effects model. An estimated pooled HR ratio was lower than 1 indicating a better effect in older patients and higher than 1 indicating a better effect in younger patients. Results: A total of 10 eligible RCTs were included in our meta-analysis. The pooled HR for overall survival (OS) comparing ICI combined with other therapies to non-ICI regimens was 0.67 (95%CI 0.58-0.78) for younger patients and 0.79 (95%CI 0.70-0.90) for older patients. The pooled HRs ratio for OS reported in older patients compared to younger patients was 1.16 (95%CI 0.99-1.34), indicating no statistically significant difference between younger and older patients. Consistent with the findings related to OS, the analysis also demonstrated that ICI-based immunotherapy could significantly prolong progression-free survival (PFS) in younger and older patients (HR = 0.55; 95% CI 0.47-0.66, and HR = 0.64; 95% CI 0.57-0.71). The same results could also be observed in the pooled HRs ratio for PFS (HR = 1.15, 95%CI 0.91-1.46) indicating comparable efficacy of ICI-based combination therapy in younger and older patients with NSCLC. Conclusion: ICI-based combination therapy vs. non-ICI treatment had comparable efficacy in younger and older NSCLC patients with a cut-off age of 65 years." @default.
• W3087788702 created "2020-10-01" @default.
• W3087788702 creator A5013134616 @default.
• W3087788702 creator A5067287490 @default.
• W3087788702 creator A5073478609 @default.
• W3087788702 creator A5079623669 @default.
• W3087788702 date "2020-09-23" @default.
• W3087788702 modified "2023-10-14" @default.
• W3087788702 title "Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis" @default.
• W3087788702 cites W1556334181 @default.
• W3087788702 cites W1600041372 @default.
• W3087788702 cites W2098923148 @default.
• W3087788702 cites W2105481352 @default.
• W3087788702 cites W2125435699 @default.
• W3087788702 cites W2126525177 @default.
• W3087788702 cites W2140497145 @default.
• W3087788702 cites W2150748567 @default.
• W3087788702 cites W2156098321 @default.
• W3087788702 cites W2169203113 @default.
• W3087788702 cites W2171075804 @default.
• W3087788702 cites W2233554134 @default.
• W3087788702 cites W2288908606 @default.
• W3087788702 cites W246286872 @default.
• W3087788702 cites W2516689248 @default.
• W3087788702 cites W2588635414 @default.
• W3087788702 cites W2588681363 @default.
• W3087788702 cites W2601447546 @default.
• W3087788702 cites W2610766845 @default.
• W3087788702 cites W2626742338 @default.
• W3087788702 cites W2753065806 @default.
• W3087788702 cites W2753529762 @default.
• W3087788702 cites W2796582438 @default.
• W3087788702 cites W2796929908 @default.
• W3087788702 cites W2797675588 @default.
• W3087788702 cites W2805354595 @default.
• W3087788702 cites W2806145489 @default.
• W3087788702 cites W2806244319 @default.
• W3087788702 cites W2808441345 @default.
• W3087788702 cites W2892640821 @default.
• W3087788702 cites W2893824814 @default.
• W3087788702 cites W2895908834 @default.
• W3087788702 cites W2898187558 @default.
• W3087788702 cites W2898352237 @default.
• W3087788702 cites W2912699866 @default.
• W3087788702 cites W2917660987 @default.
• W3087788702 cites W2919091706 @default.
• W3087788702 cites W2922258220 @default.
• W3087788702 cites W2935577863 @default.
• W3087788702 cites W2936052338 @default.
• W3087788702 cites W2944602824 @default.
• W3087788702 cites W2944844408 @default.
• W3087788702 cites W2945928820 @default.
• W3087788702 cites W2946386783 @default.
• W3087788702 cites W2946644285 @default.
• W3087788702 cites W2976744492 @default.
• W3087788702 cites W2989792268 @default.
• W3087788702 cites W2997563701 @default.
• W3087788702 cites W3000357185 @default.
• W3087788702 cites W3000564720 @default.
• W3087788702 cites W3005376436 @default.
• W3087788702 cites W4294215472 @default.
• W3087788702 doi "https://doi.org/10.3389/fonc.2020.01671" @default.
• W3087788702 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7538697" @default.
• W3087788702 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33072551" @default.
• W3087788702 hasPublicationYear "2020" @default.
• W3087788702 type Work @default.
• W3087788702 sameAs 3087788702 @default.
• W3087788702 citedByCount "21" @default.
• W3087788702 countsByYear W30877887022021 @default.
• W3087788702 countsByYear W30877887022022 @default.
• W3087788702 countsByYear W30877887022023 @default.
• W3087788702 crossrefType "journal-article" @default.
• W3087788702 hasAuthorship W3087788702A5013134616 @default.
• W3087788702 hasAuthorship W3087788702A5067287490 @default.
• W3087788702 hasAuthorship W3087788702A5073478609 @default.
• W3087788702 hasAuthorship W3087788702A5079623669 @default.
• W3087788702 hasBestOaLocation W30877887021 @default.
• W3087788702 hasConcept C126322002 @default.
• W3087788702 hasConcept C143998085 @default.
• W3087788702 hasConcept C168563851 @default.
• W3087788702 hasConcept C207103383 @default.
• W3087788702 hasConcept C2776256026 @default.
• W3087788702 hasConcept C2776999253 @default.
• W3087788702 hasConcept C44249647 @default.
• W3087788702 hasConcept C509974204 @default.
• W3087788702 hasConcept C71924100 @default.
• W3087788702 hasConcept C95190672 @default.
• W3087788702 hasConceptScore W3087788702C126322002 @default.
• W3087788702 hasConceptScore W3087788702C143998085 @default.
• W3087788702 hasConceptScore W3087788702C168563851 @default.
• W3087788702 hasConceptScore W3087788702C207103383 @default.
• W3087788702 hasConceptScore W3087788702C2776256026 @default.
• W3087788702 hasConceptScore W3087788702C2776999253 @default.
• W3087788702 hasConceptScore W3087788702C44249647 @default.
• W3087788702 hasConceptScore W3087788702C509974204 @default.
• W3087788702 hasConceptScore W3087788702C71924100 @default.
• W3087788702 hasConceptScore W3087788702C95190672 @default.
• W3087788702 hasLocation W30877887021 @default.
• W3087788702 hasLocation W30877887022 @default.
• W3087788702 hasLocation W30877887023 @default.

• next